slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment PowerPoint Presentation
Download Presentation
On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment

Loading in 2 Seconds...

play fullscreen
1 / 24

On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment - PowerPoint PPT Presentation


  • 109 Views
  • Uploaded on

Viability of non cryopreserved CD34+Stem Cells . On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment Hemobiology Department. Introduction.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'On behalf of the « Western Algerian Group of Bone Marrow Transplant » WAG-BMT Haematology and Cell Therapy Depatment' - oakley


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Viability of non cryopreserved CD34+Stem Cells

On behalf of the « Western Algerian Group of Bone Marrow Transplant »

WAG-BMT

Haematology and Cell Therapy Depatment

Hemobiology Department

introduction
Introduction
  • Autologous stem cell transplantation (ASCT) after a high dose conditioning is an established treatment modality with definitive indications for many hematological disorders.
  • However, this line of treatment requires many expensive resources, such as freezing of the harvest product in order to maintain cell viability until stem-cell reinfusion and the use of growth factors for the management of neutropenia.
aim of the study
Aim of the study
  • To study the viability of CD34+ stem cells stored at +4°C
  • To demonstrate the feasibility and the safety of the ASCT without any cryopreservation neither the use of growth factors.
study design
Study design
  • STEP 1: Short Conditioning regiments

ASCT in MM (MEL200) in 75 patients

ASCT in HL (CBV) in 17 patients

  • STEP 2: Long conditioning regiments

ASCT in HL (BEAM) in 02 patients

ASCT in HL and NHL (EAM) in 15 patients

slide5

STEP 1Material and methods

75 patients with Multiple Myeloma

Figure 1. Schema of procedure.

slide6

STEP 1Material and methods

17 patients with Hodgkin Lymphoma

slide7

STEP 1Material and methods

Wannesson L et al. Annals of Oncology 18: 623–632, 2007

step 1 material and methods
STEP 1Material and methods
  • A 2ml sample was taken from 10 collection bags and then was sent to the flow cytometry laboratory where it was stored in the refrigerator at +4°C.
  • A CD34+ stem cells count were performed using a “Lyse no wash double platform CD34+ flow cytometry assay”
  • The viability of CD34+ cells was assessed with 7'AAD immediately after the end of apherisis (H0) then at (H24), (H48) and finally at (H72).
step 1 results10
STEP 1Results

y = -1,06x + 99,3

R2 = 0,9571

p=0.05

CD34+ stem cells viability kenetic curve

slide11

STEP 1Results

Brahimi M et al. Revue Algerienne D’hematologie 2011 ; 5 :46-48.

slide12

STEP 1Results

n=200

Time of storage of the Harvest bags at +4°C

mel200 protocol
Mel200 protocol

Bekadja MA et al. Hematol Oncol Stem Cell Ther 2012; 5(1): 49-53

Bekadja MA et al. EBMT 38th meetting: Geneva, Switzerland 1-4 april 2012.page 140 (Abstract 905)

cbv protocol
CBV protocol

Bekadja MA et al. Revue Algerienne D’hematologie 2011 ; 5 :50-53.

step2 material and methods
STEP2Material and methods

15 Patients with Hodgkin Lymphoma

Bekadja MA et al. EBMT 38th meetting: Geneva, Switzerland 1-4 april 2012.page 162

(Abstract 1140)

Talhi S et al. Hématologie, Vol. 1, Supplement 1, Mars 2012: pp 213 (Abstract)

step2 results
STEP2RESULTS

n=30

Time of storage of the Harvest bags

step2 results20
STEP2RESULTS

Brahimi M et al. Unpublished data.

conclusion
Conclusion
  • We conclude that high-dose chemotherapy with non-frozen peripheral stem cells is safe in terms of haematopoietic reconstitution even without using growth factors.
slide22

Department of Hemobiology

EHU 1st November, Oran, Algeria

slide24

Chief of Biology Pôle in EHU 1stNovember

Professor Mohamed Amine BEKADJA

Bekadja MA et al. Revue Algérienne d’Hématologie 2011 ; 5 :50-53.

Bekadja MA et al. Hematol Oncol Stem Cell Ther 2012; 5(1): 49-53

Bekadja MA et al. EBMT 38th meetting: Geneva, Switzerland 1-4 april 2012., (Abstract 905)

Bekadja MA et al. EBMT 38th meetting: Geneva, Switzerland 1-4 april 2012, (Abstract 1140)